Log in

NASDAQ:AMGNAmgen Stock Price, Forecast & News

$240.69
-0.86 (-0.36 %)
(As of 08/7/2020 04:00 PM ET)
Add
Compare
Today's Range
$238.57
Now: $240.69▼
$243.62
50-Day Range
$230.32
MA: $247.34▼
$260.95
52-Week Range
$177.05
Now: $240.69▼
$264.97
Volume1.35 million shs
Average Volume2.04 million shs
Market Capitalization$140.97 billion
P/E Ratio19.66
Dividend Yield2.66%
Beta0.92
Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. It offers products for the treatment of oncology/hematology, cardiovascular, inflammation, bone health, and neuroscience. The company's products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Neulasta, a pegylated protein to treat cancer patients; Prolia to treat postmenopausal women with osteoporosis; Aranesp to treat anemia; Xgeva for skeletal-related events prevention; Sensipar/Mimpara products to treat sHPT in chronic kidney disease; and EPOGEN to treat a lower-than-normal number of red blood cells. It also markets other products in various markets, including Kyprolis, Nplate, Vectibix, Repatha, NEUPOGEN, Parsabiv, Blincyto, Aimovig, Imlygic, Corlanor, Kanjintitm, and Amgevitatm. Amgen Inc. serves healthcare providers, including physicians or their clinics, dialysis centers, hospitals, and pharmacies. It distributes its products through pharmaceutical wholesale distributors, as well as direct-to-consumer channels. The company has collaborative agreements with Novartis; UCB; Bayer HealthCare Pharmaceuticals Inc.; and DaVita Inc. Amgen Inc. was founded in 1980 and is headquartered in Thousand Oaks, California.
Read More
Amgen logo

Beat the Market (BTM) Rank™

Analyst Opinion: 2.3Community Rank: 3.0Dividend Strength: 2.5Insider Behavior: 1.0Valuation: 1.3 5 -4 -3 -2 -1 -

Overall Beat the Market Rank™

2.01 out of 5 stars


Industry, Sector and Symbol

Stock Exchange NASDAQ
Industry Biological products, except diagnostic
Sub-IndustryBiotechnology
SectorMedical
Current SymbolNASDAQ:AMGN
Previous Symbol
CUSIP03116210
CIK318154
Webwww.amgen.com
Phone805-447-1000

Debt

Debt-to-Equity Ratio3.20
Current Ratio2.18
Quick Ratio1.81

Price-To-Earnings

Trailing P/E Ratio19.66
Forward P/E Ratio15.39
P/E Growth2.04

Sales & Book Value

Annual Sales$23.36 billion
Price / Sales6.03
Cash Flow$18.91 per share
Price / Cash Flow12.73
Book Value$18.20 per share
Price / Book13.22

Profitability

EPS (Most Recent Fiscal Year)$14.82
Net Income$7.84 billion
Net Margins30.04%
Return on Equity91.98%
Return on Assets15.24%

Miscellaneous

Employees23,400
Outstanding Shares585,690,000
Market Cap$140.97 billion
Next Earnings Date11/3/2020 (Estimated)
OptionableOptionable
$240.69
-0.86 (-0.36 %)
(As of 08/7/2020 04:00 PM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive AMGN News and Ratings via Email

Sign-up to receive the latest news and ratings for AMGN and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Amgen (NASDAQ:AMGN) Frequently Asked Questions

How has Amgen's stock been impacted by COVID-19 (Coronavirus)?

Amgen's stock was trading at $198.65 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. Since then, AMGN stock has increased by 21.2% and is now trading at $240.69.
View which stocks have been most impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of Amgen?

29 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Amgen in the last year. There are currently 1 sell rating, 11 hold ratings and 17 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for Amgen.

When is Amgen's next earnings date?

Amgen is scheduled to release its next quarterly earnings announcement on Tuesday, November 3rd 2020.
View our earnings forecast for Amgen.

How were Amgen's earnings last quarter?

Amgen, Inc. (NASDAQ:AMGN) posted its quarterly earnings data on Tuesday, July, 28th. The medical research company reported $4.25 earnings per share (EPS) for the quarter, beating the consensus estimate of $3.81 by $0.44. The medical research company earned $6.21 billion during the quarter, compared to analysts' expectations of $6.19 billion. Amgen had a return on equity of 91.98% and a net margin of 30.04%. The firm's revenue was up 5.7% compared to the same quarter last year. During the same quarter last year, the business earned $3.97 EPS.
View Amgen's earnings history.

How often does Amgen pay dividends? What is the dividend yield for Amgen?

Amgen announced a quarterly dividend on Thursday, July 23rd. Investors of record on Monday, August 17th will be paid a dividend of $1.60 per share on Tuesday, September 8th. This represents a $6.40 dividend on an annualized basis and a yield of 2.66%. The ex-dividend date of this dividend is Friday, August 14th.
View Amgen's dividend history.

What guidance has Amgen issued on next quarter's earnings?

Amgen issued an update on its FY20 earnings guidance on Tuesday, July, 28th. The company provided earnings per share (EPS) guidance of $15.10-15.75 for the period, compared to the Thomson Reuters consensus earnings per share estimate of $15.63. The company issued revenue guidance of $25.0-25.6 billion, compared to the consensus revenue estimate of $25.38 billion.

What price target have analysts set for AMGN?

29 equities research analysts have issued 1-year price targets for Amgen's shares. Their forecasts range from $185.00 to $300.00. On average, they anticipate Amgen's stock price to reach $253.65 in the next year. This suggests a possible upside of 5.4% from the stock's current price.
View analysts' price targets for Amgen.

What are Wall Street analysts saying about Amgen stock?

Here are some recent quotes from research analysts about Amgen stock:
  • 1. According to Zacks Investment Research, "In 2020, while Amgen’s growth products like Prolia, Evenity, Repatha, Aimovig, Otezla and biosimilars will drive sales, increasing competition for its legacy products will continue to hurt the same. Amgen boasts a strong biosimilars portfolio. It is also progressing with its pipeline while regularly pursuing “external opportunities” such as the acquisition of Otezla and the recently acquired stake in China's BeiGene. Amgen also expects several important clinical data readouts from its innovative pipeline in 2020. However, pricing and competitive pressure are concerns. Amgen’s shares have outperformed the industry in the past one year. Estimates have gone down ahead of Q1 results due to uncertainty about the impact of the coronavirus pandemic on results. Amgen has a positive record of earnings surprise in recent quarters." (4/15/2020)
  • 2. William Blair analysts commented, "We ultimately view the deal as positive for Amgen and a good fit for management’s strategy given the low-risk nature of the deal and immediate accretion." (8/30/2019)
  • 3. Evercore ISI analysts commented, "We used a discount rate which is a function of cost of equity and cost of debt. Terminal growth rate estimates were used to derive future cash flows." (8/11/2019)

Has Amgen been receiving favorable news coverage?

News stories about AMGN stock have trended negative this week, according to InfoTrie Sentiment Analysis. The research firm identifies negative and positive news coverage by monitoring more than six thousand blog and news sources in real-time. The firm ranks coverage of companies on a scale of negative five to five, with scores nearest to five being the most favorable. Amgen earned a media sentiment score of -2.0 on InfoTrie's scale. They also assigned news stories about the medical research company a news buzz of 0.0 out of 10, indicating that recent news coverage is extremely unlikely to have an effect on the company's share price in the immediate future.
View the latest news about Amgen.

Are investors shorting Amgen?

Amgen saw a decline in short interest in the month of July. As of July 31st, there was short interest totaling 5,500,000 shares, a decline of 8.8% from the July 15th total of 6,030,000 shares. Based on an average daily volume of 2,720,000 shares, the days-to-cover ratio is currently 2.0 days. Approximately 0.9% of the company's shares are short sold.
View Amgen's Short Interest.

Who are some of Amgen's key competitors?

Some companies that are related to Amgen include Gilead Sciences (GILD), Celgene (CELG), Vertex Pharmaceuticals (VRTX), Regeneron Pharmaceuticals (REGN), Biogen (BIIB), Seattle Genetics (SGEN), Alexion Pharmaceuticals (ALXN), BioMarin Pharmaceutical (BMRN), Incyte (INCY), Alnylam Pharmaceuticals (ALNY), EXACT Sciences (EXAS), Neurocrine Biosciences (NBIX), Immunomedics (IMMU), Novavax (NVAX) and Repligen (RGEN).
View all competitors.

What other stocks do shareholders of Amgen own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Amgen investors own include Johnson & Johnson (JNJ), Walt Disney (DIS), NVIDIA (NVDA), Alibaba Group (BABA), Intel (INTC), Cisco Systems (CSCO), Pfizer (PFE), AT&T (T), Gilead Sciences (GILD) and AbbVie (ABBV).

Who are Amgen's key executives?

Amgen's management team includes the following people:
  • Mr. Robert A. Bradway, Chairman, CEO & Pres (Age 56)
  • Mr. David W. Meline, Exec. VP & CFO (Age 62)
  • Mr. Jonathan P. Graham, Sr. VP, Gen. Counsel & Sec. (Age 58)
  • Dr. David M. Reese M.D., Exec. VP of R&D (Age 56)
  • Mr. Murdo Gordon, Exec. VP of Global Commercial Operations (Age 52)

What is Amgen's stock symbol?

Amgen trades on the NASDAQ under the ticker symbol "AMGN."

Who are Amgen's major shareholders?

Amgen's stock is owned by a number of institutional and retail investors. Top institutional investors include LSV Asset Management (0.49%), Sumitomo Mitsui Trust Holdings Inc. (0.46%), Swiss National Bank (0.40%), PNC Financial Services Group Inc. (0.29%), New York State Common Retirement Fund (0.23%) and Coho Partners Ltd. (0.18%). Company insiders that own Amgen stock include Cynthia M Patton, David Piacquad, David W Meline, Jonathan P Graham, R Sanders Williams, Ronald D Sugar and Tyler Jacks.
View institutional ownership trends for Amgen.

Which institutional investors are selling Amgen stock?

AMGN stock was sold by a variety of institutional investors in the last quarter, including Pzena Investment Management LLC, LSV Asset Management, MERIAN GLOBAL INVESTORS UK Ltd, Envestnet Asset Management Inc., New York State Common Retirement Fund, Ziegler Capital Management LLC, Gateway Investment Advisers LLC, and Zurcher Kantonalbank Zurich Cantonalbank. Company insiders that have sold Amgen company stock in the last year include Cynthia M Patton, David Piacquad, David W Meline, Jonathan P Graham, R Sanders Williams, and Ronald D Sugar.
View insider buying and selling activity for Amgen.

Which institutional investors are buying Amgen stock?

AMGN stock was acquired by a variety of institutional investors in the last quarter, including Raymond James Financial Services Advisors Inc., Robeco Institutional Asset Management B.V., Sumitomo Mitsui Trust Holdings Inc., Wedge Capital Management L L P NC, Cullinan Associates Inc., Principal Financial Group Inc., SG Americas Securities LLC, and Sawgrass Asset Management LLC.
View insider buying and selling activity for Amgen.

How do I buy shares of Amgen?

Shares of AMGN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Amgen's stock price today?

One share of AMGN stock can currently be purchased for approximately $240.69.

How big of a company is Amgen?

Amgen has a market capitalization of $140.97 billion and generates $23.36 billion in revenue each year. The medical research company earns $7.84 billion in net income (profit) each year or $14.82 on an earnings per share basis. Amgen employs 23,400 workers across the globe.

What is Amgen's official website?

The official website for Amgen is www.amgen.com.

How can I contact Amgen?

Amgen's mailing address is ONE AMGEN CENTER DRIVE, THOUSAND OAKS CA, 91320. The medical research company can be reached via phone at 805-447-1000 or via email at [email protected]

This page was last updated on 8/10/2020 by MarketBeat.com Staff
Receive Analysts' Upgrades and Downgrades Daily

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.